文献速递肝病

美国商业保险人群中酒精性肝硬化的高负担

The high burden of alcoholic cirrhosis in privately insured persons in the United States.
PubMed 文献 · Hepatology · 2018-05-20

该研究基于2009—2015年美国Truven MarketScan商业索赔数据库,纳入18—64岁酒精性肝硬化(AC)患者,按全国雇主投保人群加权计算患病率、门脉高压并发症及费用。2015年肝硬化患者294,215例,其中AC 105,871例(36%);7年间肝硬化患病率从0.19%升至0.27%,AC从0.07%升至0.10%(均P<0.001)。与非AC相比,AC患者诊断时门脉高压并发症更多、住院与再入院更多、首年人均费用近乎翻倍(44,835美元 vs 23,319美元)。

要点

  • 2015年商业保险肝硬化患者中36%为酒精性肝硬化,7年间AC患病率从0.07%升至0.10%(P<0.001)。
  • AC患者诊断时门脉高压并发症显著多于非AC,每年每100名参保者多25例肝硬化住院和6.3例酒精相关住院。
  • AC患者诊断后首年人均费用近乎翻倍(44,835美元 vs 23,319美元)。

核心结论

  • 在全国代表性商业保险人群中,AC参保者就诊时病情更重、住院和再入院更频繁,人均医疗费用近乎为非AC者的两倍。

研究设计与样本

  • 基于Truven MarketScan商业索赔与 encounters 数据库(2009—2015年)的队列研究,纳入18—64岁经ICD-9和ICD-10编码识别的AC患者,按全国雇主投保商业保险人群加权计算年患病率,采用竞争风险分析估计门脉高压并发症事件率及AC与费用、入院和再入院的关联。

主要发现

  • 2015年肝硬化患者294,215例,其中AC 105,871例(36%);AC诊断平均年龄53.5岁,女性占32%。
  • 7年间全国加权肝硬化患病率从0.19%升至0.27%(P<0.001),AC从0.07%升至0.10%(P<0.001)。
  • 与非AC相比,AC参保者诊断时门脉高压并发症显著更多,每年每100名参保者多25例肝硬化住院和6.3例酒精相关住院,全因再入院也更多。
  • AC患者诊断后首年人均费用近乎翻倍(44,835美元 vs 23,319美元)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Alcoholic cirrhosis (AC) is a major cause of liver-related morbidity and mortality in the United States. Rising rates of alcohol use disorders in the United States will likely result in more alcoholic liver disease. Our aim was to determine the prevalence, health care use, and costs of AC among privately insured persons in the United States. We collected data from persons aged 18-64 with AC (identified by codes from the International Classification of Diseases, Ninth and Tenth Revisions) enrolled in the Truven MarketScan Commercial Claims and Encounters database (2009-2015). We determined yearly prevalence, weighted to the national employer-sponsored, privately insured population. Using competing risk analysis, we estimated event rates for portal hypertensive complications and estimated the association between AC and costs as well as admissions and readmissions. In 2015, 294,215 people had cirrhosis and 105,871 (36%) had AC. Mean age at AC diagnosis was 53.5 years, and 32% were women. Over the 7 years queried, estimated national cirrhosis prevalence rose from 0.19% to 0.27% (P < 0.001) and for AC from 0.07% to 0.10% (P < 0.001). Compared to non-AC, AC enrollees were significantly more likely to have portal hypertensive complications at diagnosis and higher yearly cirrhosis and alcohol-related admissions (25 excess cirrhosis admissions and 6.3 excess alcohol-related admissions per 100 enrollees) as well as all-cause readmissions. Per-person costs in the first year after diagnosis nearly doubled for AC versus non-AC persons (US$ 44,835 versus 23,319). CONCLUSION: In a nationally representative cohort of privately insured persons, AC enrollees were disproportionately sicker at presentation, were admitted and readmitted more often, and incurred nearly double the per-person health care costs compared to those with non-AC. (Hepatology 2018).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018. PMID: 29579356. doi:10.1002/hep.29887

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。